What is OncoHost?
OncoHost operates at the intersection of life sciences and artificial intelligence, aiming to revolutionize cancer treatment through personalized strategies. The company's core technology, the PROphet® platform, utilizes proprietary proteomic analysis of blood samples to monitor the host's biological response to cancer therapies. This detailed profiling provides predictive insights into individual patient outcomes, enabling more tailored treatment planning. By identifying potential drug targets and understanding the dynamics of therapy resistance, OncoHost is poised to advance novel therapeutic strategies and combination therapies, addressing a critical challenge in clinical oncology.
How much funding has OncoHost raised?
OncoHost has raised a total of $43M across 2 funding rounds:
Series B
$8M
Series C
$35M
Series B (2021): $8M with participation from OurCrowd
Series C (2022): $35M led by ALIVE Israel HealthTech VC, OurCrowd, Leumi Partners, and Menora Mivtachim
Key Investors in OncoHost
Leumi Partners
Leumi Partners is a leading Israeli financial firm specializing in investment banking and research services, offering direct strategic investments, underwriting, advisory, and M&A services. Established in 1980, it is recognized as Israel's premier merchant and investment banking platform.
OurCrowd
OurCrowd is an investment platform founded in 2013, enabling accredited investors and institutions to invest in startups and venture funds, with a focus on companies based in Israel.
Menora Mivtachim
Menora Mivtachim Holdings, founded in 1935, is one of Israel's largest insurance and finance groups, specializing in asset management and operating the largest pension fund in Israel.
What's next for OncoHost?
With the recent major strategic investment, OncoHost is positioned for significant growth and expansion of its PROphet® platform. The company's focus on personalized medicine and overcoming therapy resistance aligns with the evolving landscape of cancer care. Future developments are likely to involve further clinical validation, broader adoption of the PROphet® platform by healthcare providers, and potential partnerships to integrate its insights into drug development pipelines. The enterprise-level backing suggests a strategic focus on scaling operations and solidifying its market position in the competitive oncology sector.
See full OncoHost company page
